Test Forum :  Fourthcity Forum The fastest message board... ever.
This is a test forum. Feel free to delete it or edit after installation. 
Goto Thread: PreviousNext
Goto: Forum ListMessage ListNew TopicSearchLog In
Global Octreotide Market Overview
Posted by: sonn2019 (IP Logged)
Date: September 30, 2019 09:33AM

Global Octreotide Market Overview



Solution: 50 mcg SC q8hr initially; titrate up to 500 mcg SC q8hr if necessary; after successful treatment with solution for 2 weeks, initiate treatment with suspension (depot injection)
Suspension (depot injection): 20 mg IM (gluteal) every 4 weeks for 3 months; titrate up or down to 10-30 mg IM every 4 weeks, depending on response; not to exceed 40 mg, as follows
Symptoms controlled: If GH < 1 ng/mL and IGF-1 normal, decrease dose to 10 mg IM intragluteally every 4 weeks; if GH < 2.5 ng/mL and IGF-1 normal, maintain dose at 20 mg IM every 4 weeks
Symptoms uncontrolled: If GH > 2.5 ng/mL or IGF-I elevated, increase dose to 30 mg IM every 4 weeks; if symptoms persist, increase to 40 mg IM
Dosing Considerations
Monitor IGF-1 levels every 2 weeks to guide titration; goal: GH levels <5 ng/mL or IGF-1 levels <1.9 units/mL (men) and <2.2 units/mL (women)
Monitor IGF-1 or GH levels every 6 months
Withdraw drug yearly for 4 weeks (solution) or 8 weeks (suspension) from patients who have undergone irradiation to assess
Carcinoid Tumor

Solution: 100-600 mcg/day SC divided q6-12hr; may titrate to 1500 mcg/day; after successful treatment with solution for 2 weeks, initiate treatment with suspension (depot injection)
Suspension (depot injection): 20 mg IM every 4 weeks for 2 months then modify dose based on response; may increase to 30mg q4wk if symptoms are inadequately controlled; decrease to 10 mg IM q4wk for trial period if initially responsive to 20 mg dose; dose >30 mg not recommended
VIPoma

Solution: 200-300 mcg/day SC divided q6-12hr; after successful treatment with solution for 2 weeks, initiate treatment with suspension (depot injection)
Suspension (depot injection): Patients must be stabilized on subcutaneous Octreotide powder for at least 2 weeks before switching to long-acting depot; upon switch, administer 20 mg IM intragluteally every 4 weeks for 2 months; continue solution for first 2 weeks; titrate suspension up or down to 10-30 mg IM every 4 weeks
Esophageal Variceal Bleeding (Off-label)

Solution: 25-100 mcg IV bolus (usual bolus dose: 50 mcg); follow by continuous IV infusion of 25-50 mcg/hr for 2-5 days; may repeat bolus in first hr if hemorrhage not controlled



Sorry, only registered users may post in this forum.
This forum powered by Phorum.